

(51) International Patent Classification:
A61K 31/575 (2006.01)(21) International Application Number:
PCT/US2015/062743(22) International Filing Date:
25 November 2015 (25.11.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/084,769 26 November 2014 (26.11.2014) US(71) Applicant: ENANTA PHARMACEUTICALS, INC.
[US/US]; 500 Arsenal Street, Watertown, MA 02472 (US).

(72) Inventors: OR, Yat, Sun; 169 Fayette Street, Watertown, MA 02472 (US). SHEN, Ruichao; 563 Lagrange Street, West Roxbury, MA 02132 (US). DAI, Peng; 85 Auburn Street, Auburndale, MA 02466 (US). LONG, Jiang; 15 Wallace Road, Wayland, MA 01778 (US). XING, Xuechao; 20 Cedar Street, Wilmington, MA 01887 (US). WANG, Guoqiang; 65 Becket Road, Belmont, MA 02478 (US).

(74) Agents: HARLAN, Edgar, W. et al.; Elmore Patent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.